Pfenex (NYSEAMERICAN:PFNX) released its earnings results on Thursday. The biotechnology company reported $0.09 earnings per share (EPS) for the quarter, meeting the Zacks’ consensus estimate of $0.09, Fidelity Earnings reports. The company had revenue of $15.25 million during the quarter, compared to analysts’ expectations of $14.80 million.
Shares of NYSEAMERICAN PFNX opened at $10.67 on Friday. Pfenex has a 1 year low of $3.13 and a 1 year high of $11.39.
In other Pfenex news, insider Patrick K. Lucy sold 6,000 shares of Pfenex stock in a transaction dated Monday, September 16th. The stock was sold at an average price of $10.01, for a total transaction of $60,060.00.
Pfenex Company Profile
Pfenex Inc, a clinical-stage development and licensing biotechnology company, focuses on developing protein therapies for unmet patient needs. Its lead product candidates include PF708, a therapeutic equivalent drug candidate to Forteo (teriparatide) for the treatment of osteoporosis; and novel anthrax vaccine candidates, such as Px563L and RPA563 that have completed Phase Ia clinical study.
Receive News & Ratings for Pfenex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfenex and related companies with MarketBeat.com's FREE daily email newsletter.